<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007224</url>
  </required_header>
  <id_info>
    <org_study_id>CORDUS</org_study_id>
    <nct_id>NCT04007224</nct_id>
  </id_info>
  <brief_title>Oxytocin Versus Cord Blood for Improving Autistic Disorder</brief_title>
  <official_title>Comparison of Oxytocin and Umbilical Cord Blood for Improving Autistic Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundatia Bio-Forum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spitalul Angiomedica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundatia Bio-Forum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study evaluates in an open-label, crossover design the comparative efficacy and
      safety of intranasal oxytocin and autologous umbilical cord blood for improving the
      functioning of children with autistic spectrum disorder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children aged 3-7 years diagnosed with autistic spectrum disorder and who did not previously
      receive oxytocin or umbilical cord blood treatments, will be enrolled to receive both
      treatments in random order. Assessment of functioning impairment will be done with
      QCHAT/M-CHAT/CAST questionnaires initially, at 2 months, 6 months and 1 year after first
      treatments. Either oxytocin or cord blood will be administered initially and at visit 2,
      which will take place at 2 months. All children will receive both treatments. A total of
      25-40 children are expected to enroll and complete the study.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in behaviour, interaction with family and peers</measure>
    <time_frame>At 2 months after administration of either treatment</time_frame>
    <description>change in scores on M-CHAT (Modified Checklist for Autism in Toddlers) questionnaire; total score, maximum 20, lower is better</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in behavior and social interaction</measure>
    <time_frame>At 2 months after administration of either treatment</time_frame>
    <description>change in score on Q-CHAT (Quantitative Checklist for Autism in Toddlers) questionnaire; total score, maximum 100, lower is better</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in overall functioning of the child</measure>
    <time_frame>At 2 months after administration of either treatment</time_frame>
    <description>change in score on CAST (The Childhood Autistic Spectrum Test) questionnaire; Total score, maximum 39, lower is better</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Autistic Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal Oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous umbilical cord blood</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of autologous umbilical cord blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal oxytocin</intervention_name>
    <description>daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>non-invasive treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous umbilical cord blood</intervention_name>
    <description>patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth</description>
    <arm_group_label>Autologous umbilical cord blood</arm_group_label>
    <other_name>invasive treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of autistic spectrum disorder

        Exclusion Criteria:

          -  metabolic or genetic disorder (ex storage disease, Down, etc),
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felician Stancioiu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundatia Bio-Forum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spitalul Angiomedica</name>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <zip>040245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <link>
    <url>https://bio-forum.net/clinical-trials</url>
    <description>short info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT04007224/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

